ClinicalTrials.gg
WithdrawnNCT07100925Updated Jun 25, 2026

A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell Carcinoma

A Phase 1 interventional study of tolododekin alfa in Cutaneous Squamous Cell Carcinoma (CSCC), Renal Transplant and Solid Tumor, sponsored by Ankyra Therapeutics, Inc. Withdrawn. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Ankyra Therapeutics, Inc · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Strategic realignment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).

02

Conditions studied

  • Cutaneous Squamous Cell Carcinoma (CSCC)
  • Renal Transplant
  • Solid Tumor
  • Solid Tumor Cancer

Keywords

  • intratumoral injection
  • intratumoral
03

In context

Lead sponsor

Ankyra Therapeutics, Inc is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have or cytologically confirmed high-risk and/or locoregionally CSCC
  2. Have per Version 1.1 (RECIST v1.1)
  3. Are renal allograft recipients on a stable regimen.
  4. Have adequate renal function defined as ≥ 30 mL/min as determined by the Cockcroft-Gault equation.
  5. Have an (ECOG) performance status of 0 to 2.
  6. Have a > 12 months.
  7. Have baseline (EKG) without evidence of acute ischemia or prolonged
  8. Heterosexually active women of (WOCBP) must agree to use at least 2 forms of highly effective methods of
  9. All male participants who are not sterile must commit to the use of a reliable method of birth control or abstinence.
  10. Last dose of previous anticancer therapy (including agents) ≥ 28 days or surgical intervention ≥ 21 days prior to the first dose of study drug.
  11. Resolution of all prior anticancer therapy toxicities (except for alopecia or vitiligo) to ≤ Grade 1
  12. Willingness to provide fresh tumor specimens
  13. Capable of understanding and complying with protocol requirements.
  14. Provides written for the study.

Exclusion criteria

Exclusion Criteria:

  1. Have AJCC Stage IV disease, known distant , or findings on imaging that are considered to be highly suspicious for distant metastasis.
  2. Have injectable tumors impinging upon major airways or blood vessels.
  3. Have had prior treatment with recombinant interleukin-12 (IL-12).
  4. Have had prior radiation therapy within 28 days for CSCC at the site of injection.
  5. Have received within 28 days prior to the start of study drug (C1D1).
  6. Have any history of transplant-related deoxyribonucleic acid (DNA) viral infections, such as human polyomavirus 1 (BKV), Epstein-Barr virus (EBV), or cytomegalovirus (CMV) within 3 months of C1D1.
  7. Have primary or acquired immunodeficient states (e.g., leukemia, lymphoma) requiring active therapy.
  8. A who has a positive serum pregnancy test prior to C1D1 or female participant who is breastfeeding
  9. Have known active uncontrolled , (HCV), or (HIV) infection.
  10. Have active disease or medical conditions requiring chronic (i.e., ≥ 20 mg/day prednisone or equivalent) or other therapy beyond that required for maintenance allograft rejection prevention.
  11. Have congestive heart failure, active coronary artery disease, unevaluated new onset angina, unstable angina, or cardiac arrhythmias.
  12. Have uncontrolled bleeding disorders.
  13. Have a history of allergic reactions attributed to compounds of similar biological composition to IL-12, aluminum hydroxide, or drugs formulated with polysorbate-20.
  14. Have other systemic conditions or organ abnormalities that may interfere with the conduct the current study.
  15. Have any acute or chronic psychiatric problems or substance abuse disorder that make the participant unsuitable for participation.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    tolododekin alfa (ANK-101) IT Injection

    Participants will receive 2 cycles of tolododekin alfa before surgical resection of CSCC tumor

    Drug: tolododekin alfa

Interventions

  • IT administration of ANK-101 once every 3 weeks for 2 cycles, followed by surgical resection

06

What researchers measure

Primary outcomes

  1. Major Pathological Response (MPR) rate

    The percentage of participants who have ≤ 10% viable cancer cells in the surgical pathology sample among all response evaluable participants.

    Time frame: 3 months

Secondary outcomes

  1. Event Free Survival (EFS)

    Time from the first dose of tolododekin alfa to date of event

    Time frame: Up to 3 years

  2. Relapse Free Survival (RFS)

    Time from surgical resection to the earliest date of relapse or death from any cause.

    Time frame: Up to 3 years

  3. Pathological Complete Response (pCR)

    The percentage of participants with complete absence of viable cancer cells in the surgical pathology sample among all response evaluable participants.

    Time frame: 3 months

  4. Best Overall Response Rate (BORR)

    The percentage of participants with a complete response (CR) or partial response (PR) per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 among all response evaluable participants.

    Time frame: Up to 3 years

  5. Overall Survival (OS)

    The time from the administration of tolododekin alfa to death from any cause

    Time frame: Up to 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Jun 2030, 54 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 3, 2025
StartEst.
Dec 15, 2025
Primary completionEst.
Jun 2030
CompletionEst.
Dec 2030
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07100925
Lead sponsor
Ankyra Therapeutics, Inc
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Dec 15, 2025 (estimated)
Primary completion
Jun 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jun 25, 2026

Study contacts

Joe Elassal, MD, MBA
study director · Ankyra Therapeutics
Ann Silk, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolododekin alfa

Start the discussion